Horizon Therapeutics | Patient Daily

Horizon Therapeutics

Patient Daily | May 7, 2023

Horizon Therapeutics plc Reports First-Quarter 2023 Financial Results

Patient Daily | May 7, 2023

Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Lupus Nephritis

Patient Daily | May 7, 2023

Horizon Therapeutics plc Ranks First in Patient Centricity and Integrity by Patient Advocacy Groups According to New PatientView Survey

Patient Daily | May 7, 2023

Horizon Therapeutics plc Announces Initiation of Phase 3 Clinical Trial in Japan Evaluating TEPEZZA® (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)

Patient Daily | May 7, 2023

Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)

Patient Daily | Apr 24, 2023

Horizon Therapeutics plc Announces UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be Presented at the 2023 American Academy of Neurology (AAN) Annual Meeting

Patient Daily | Apr 24, 2023

Horizon Therapeutics plc and Massachusetts Institute of Technology (MIT) Solve Announce the Launch of the Third Annual Horizon Prize to Inspire Sustainable Solutions for Research and Care in the Rare Disease Community

Patient Daily | Apr 24, 2023

Horizon Therapeutics Announces Date of Irish Court Hearing to Sanction Scheme of Arrangement

Trending

Patient Daily | Mar 14, 2025

Founder of Medfluence Advisors on healthcare marketing: 'The patient journey is more complex than ever'

Patient Daily | Mar 14, 2025

Doctor on weather-related pressure headaches: This could happen 'if you have an underlying chronic sinus disease'

C.D. Marsden | Mar 14, 2025

Solidarity Health to Musk, RFK, Jr: ‘Enforce the CMS Hospital Price Transparency Rule’